The Fellow on Call: The Heme/Onc Podcast

The hosts dive into the complex world of relapsed and refractory acute myeloid leukemia, discussing how to define primary induction failure and exploring various treatment options. They highlight innovative strategies like FLAG and CLAG regimens to enhance cytarabine's effectiveness. The conversation also addresses the role of targeted therapies and the significance of clinical trials in improving outcomes. Personal stories add a relatable touch, making this evolving treatment landscape even more engaging.

Explore innovative treatment strategies for elderly patients with acute myeloid leukemia who can't handle intensive therapy. Learn about assessing fitness for treatment and the significance of genetic mutations. Discover how modern therapies like azacitidine and venetoclax are reshaping care for frail patients. Key clinical trials, including Viali-A and LACEWING, reveal improved outcomes. The episode delivers valuable insights into navigating the complexities of AML management in older, less fit patients.

Dr. Amar Kelkar, a hematology and oncology expert from Dana-Farber Cancer Institute, delves into allogeneic transplant options for acute myeloid leukemia (AML). He discusses the various conditioning regimens and how to choose the best one for patients. The conversation also highlights the critical role of measurable residual disease testing and maintenance therapies. Kelkar sheds light on graft-versus-host disease and recent advancements in haploidentical transplants, addressing racial disparities in transplant outcomes for better equity.

Dr. Amar Kelkar, an instructor at Harvard Medical School and specialist at Dana-Farber, joins for an enlightening dive into allogeneic transplants for AML. He unpacks key eligibility criteria for patients, stressing the importance of minimal residual disease status. The conversation also illuminates the critical role of HLA matching and donor selection factors. Additionally, Dr. Kelkar compares various stem cell sources, revealing unique insights about outcomes in haploidentical and cord blood transplants. His expert perspective makes this complex topic accessible.

This discussion highlights cutting-edge maintenance therapies for acute myeloid leukemia (AML). It reviews the role of cytarabine consolidation and the significance of hypomethylating agents in restoring gene function. Personal anecdotes enrich insights on the treatment journey of patients. Challenges surrounding targeted therapies, especially FLT3 inhibitors, are explored alongside the promising drug giltaritinib. The importance of evaluating clinical trial data to enhance patient outcomes is emphasized, making for a comprehensive overview of AML therapies.

Delve into the complexities of consolidation therapies for acute myeloid leukemia (AML). Discover the pivotal role of allogeneic stem cell transplants in improving patient outcomes. Learn about high-dose vs. lower-dose cytarabine treatments and their effects on relapse prevention. Explore the evolution of transplant techniques, including donor matching and conditioning methods. Plus, see how minimal residual disease (MRD) testing shapes treatment strategies, potentially minimizing unnecessary transplants while boosting survival rates.

Dive into the fascinating world of Acute Myeloid Leukemia treatment! Discover the essential phases of consolidation and maintenance therapy to prevent relapse. The discussion highlights genetic abnormalities and their impact on patient care, including who qualifies for allogeneic transplants. Get insights on the latest advancements in consolidation strategies, especially the effectiveness of high-dose cytarabine. Personal stories and lighthearted moments make complex topics engaging!

Dive into the world of acute myeloid leukemia (AML) induction therapy with an in-depth look at treatment options and dosing strategies. The discussion unveils the significance of the FLAG regimen, patient selection for add-ons, and the evolving landscape of targeted therapies. Insights into the development of gemtuzumab ozogamicin and the role of genetic testing highlight the complexities of tailoring treatments. Plus, enjoy a light-hearted moment as the hosts celebrate their love for fall decorations amidst the serious topics!

Dive into the complexities of Acute Myeloid Leukemia (AML) induction therapy! Discover the '7+3' chemotherapy regimen, its historical roots, and how different mutations impact treatment decisions. Learn about the essential drug, citarabine, and the strategies behind its administration for optimal effectiveness. The discussion even touches on patient case studies and the evolution of AML treatments through randomized trials, making it both engaging and informative!

Dive into the intricacies of Acute Myeloid Leukemia treatment, starting with essential definitions and an overview. Learn the vital role of leukapheresis and cytoreduction when faced with high blast levels. Explore the importance of molecular testing for effective risk stratification and treatment planning. Discover the phases of AML treatment, emphasizing morphologic remission and response criteria. Tune in for a blend of clinical insights and engaging anecdotes that illuminate this complex topic.